Quadrant Capital Group LLC Akero Therapeutics, Inc. Transaction History
Quadrant Capital Group LLC
- $1.42 Billion
- Q3 2024
A detailed history of Quadrant Capital Group LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 573 shares of AKRO stock, worth $16,811. This represents 0.0% of its overall portfolio holdings.
Number of Shares
573
Previous 573
-0.0%
Holding current value
$16,811
Previous $13,000
23.08%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$232 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$208 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$174 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$164 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$154 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.36B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...